Matinas BioPharma Holdings Debt-to-Assets Ratio Growth & History (MTNB)

Matinas BioPharma Holdings's debt-to-assets ratio was 0.19 for fiscal 2025.

View full Matinas BioPharma Holdings company overview

Matinas BioPharma Holdings annual debt-to-assets ratio history

Matinas BioPharma Holdings annual debt-to-assets ratio

Fiscal yearPeriod endedDebt-to-assets ratioChangeGrowth
20252025-12-310.19−0.04−17.95%
20242024-12-310.230.09+61.62%
20232023-12-310.140.05+53.94%
20222022-12-310.090.02+19.98%
20212021-12-310.080.02+45.09%
20202020-12-310.05−0.05−49.69%
20192019-12-310.11
20172017-12-310.010.00+144.19%
20162016-12-310.000.00+100.62%
20152015-12-310.00−0.02−92.45%
20142014-12-310.020.02
20132013-12-310.00

Matinas BioPharma Holdings debt-to-assets ratio trends

Over the last five fiscal years, Matinas BioPharma Holdings's debt-to-assets ratio increased from 0.05 to 0.19, a change of 0.13. The latest reported quarter, Q2 2026, shows 0.00.

About the metric

What the debt-to-assets ratio means

The debt-to-assets ratio shows the portion of a company’s reported assets financed with interest-bearing debt. It is a leverage measure and should not be confused with total liabilities divided by assets.

Calculation and source

How debt-to-assets is calculated

TickerStat calculates debt-to-assets as total interest-bearing debt divided by total assets at the same reporting-period end. Periods with missing debt or non-positive assets are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.

Review Matinas BioPharma Holdings source filings ↗

Community posts

It’s quiet here.

No posts about MTNB yet. Start the conversation.

Write the first post